目的 探讨心舒宝胶囊联合缬沙坦胶囊治疗高血压的临床疗效。方法 选取2019年3月-2020年8月在平煤神马医疗集团总医院就诊的150例高血压患者，按照随机数字表法将所有患者分为对照组和治疗组，每组各75例。对照组口服缬沙坦胶囊，80 mg/次，1次/d。治疗组在对照组基础上口服心舒宝胶囊，0.5 g/次，3次/d。两组患者连续治疗3个月。观察两组的临床疗效，比较两组的血压、血清内皮素-1（ET-1）、血管紧张素Ⅱ（AngⅡ）、同型半胱氨酸（Hcy）水平。结果 治疗后，治疗组的总有效率为94.67%，对照组的总有效率为84.00%，组间比较差异有统计学意义（P<0.05）。治疗后，两组的24 h平均收缩压（24 h SBP）、24 h平均舒张压（24 h DBP）、收缩压变异性（SBPV）、舒张压变异性（DBPV）均明显降低（P<0.05）；且治疗组的24 h SBP、24 h DBP、SBPV、DBPV低于对照组，差异有统计学意义（P<0.05）。治疗后，两组血清ET-1、AngⅡ、Hcy水平明显降低（P<0.05）；且治疗后治疗组的ET-1、AngⅡ、Hcy水平低于对照组，差异有统计学意义（P<0.05）。结论 心舒宝胶囊联合缬沙坦胶囊可提高临床疗效，降低血压，减轻血管内皮功能损伤，安全性良好。

Objective To investigate the clinical efficacy of Xinshubao Capsules combined with Valsartan Capsules in treatment of hypertension. Methods Patients (150 cases) with hypertension in Pingmei Shenma Group General Hospital from March 2019 to August 2020 were randomly divided into control and treatment groups, and each group had 75 cases. Patients in the control group were po administered with Valsartan Capsules, 80 mg/time, once daily. Patients in the treatment group were po administered with Xinshubao Capsules on the basis of the control group, 0.5 g/time, three times daily. Patients in two groups were treated for 3 months. After treatment, the clinical efficacies were evaluated, and the blood pressure, the levels of ET-1, Ang Ⅱ, and Hcy in two groups were compared. Results After treatment, the total effective rates were 94.67% and 84.00% in the treatment group and the control group, and the difference was statistically significant (P<0.05). After treatment, the 24 h SBP, 24 h DBP, SBPV, and DBPV of two groups were significantly decreased (P<0.05). And the 24 h SBP, 24 h DBP, SBPV, and DBPV of the treatment group were lower than those of the control group, and the difference was statistically significant (P<0.05). After treatment, the serum levels of ET-1, Ang Ⅱ, and Hcy in two groups were significantly decreased (P<0.05). After treatment, the levels of ET-1, Ang Ⅱ, and Hcy in the treatment group were lower than those in the control group, and the difference was statistically significant (P<0.05). Conclusion Xinshubao Capsules combined with Valsartan Capsules can improve the curative effect of hypertension, reduce the variability of blood pressure, alleviate the damage of vascular endothelial function, with good safety.

R972

河南省医学科技攻关计划项目（LHGJ20191463）